Oct 16, 2018
WOODCLIFF LAKE, N.J., Oct. 16, 2018 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that 5 poster presentations reporting new research on human genetics guided drug discovery will be highlighted at the American Society of Human Genetics (ASHG) Conference 2018, in San Diego from Oct 16-20, 2018. In addition, a video will be shown throughout the conference that profiles the new Eisai Center for Genetics Guided Dementia Discovery (G2D2) being established in Cambridge, Mass.
The Eisai presentations will highlight new research using insights from human genetics to guide drug discovery in immuno-dementia and immuno-oncology. In addition, they will describe new scientific resources developed by Eisai for the broader genetics community, including the Target Gene Notebook – an informatics platform to enable collation, integration and application of genetic and other data for drug discovery.
As previously announced, Eisai is establishing the new G2D2 center in a 50,000 sq. ft. state-of-the-art research facility in Cambridge, Mass., currently scheduled to be completed in spring 2019. The ASHG video will profile this new Center, including its focus on discovering novel therapeutics for dementia that target human genetics-identified immune mechanisms by applying novel precision chemistry approaches and through research collaborations.
"We are pleased to be able to share and discuss the genetics work going on at Eisai with the broader scientific community at ASHG," said Dr. Janna Hutz, Head of Data Science & Scientific Infrastructure. "The results and tools we will be sharing have come from exciting applications of genetics by Eisai scientists and our collaborators to our ongoing drug discovery efforts in dementia and oncology. We believe that the scientific discussions that occur at meetings like ASHG are critical to informing our drug discovery efforts."
"The new Eisai Center for Genetics Guided Dementia Discovery will be dedicated to cutting-edge and multi-disciplinary collaborative research through the lens of human genetics to discover and develop new medicines that can positively impact the health of patients and their families," said Dr. Nadeem Sarwar, Founder and President of G2D2. "The research being presented at ASHG, as well as the video profiling the new Center, exemplifies the innovative scientific approaches this new center will employ."
Poster presentations at ASHG 2018:
3:00PM Wed Oct 17th
Immune cell tumor infiltration in TCGA: A genome-wide association study
2:00PM Thu Oct 18th
Target Gene Notebook: Putting genetics to work for drug discovery
Mary Pat Reeve
2:00PM Thu Oct 18th
CD33 and Alzheimer's disease: Functional and association analysis of a frame shift variant
2:00PM Thu Oct 18th
Application of human genetics to launch and guide the discovery of a novel cancer immunotherapy
3:00PM Thu Oct 18th
Transcriptomic association analysis with Alzheimer's disease related traits on ROS/MAP, MSBB, and Mayo Clinic cohorts
About Eisai Inc.
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.
SOURCE Eisai Inc.